Specifically, a polymorphism at position −238 in the promoter region (rs361525) has previously shown conflicting data regarding the response to anti-TNF-α treatment in rheumatoid arthritis, psoriasis, and IBDs [25,35,36]. The gene discussed is TNF; the disease is psoriasis.